- What Clinical Trial Insurance Covers in a Trial Context
- Why Latin America Has Its Own Insurance Considerations
- Country-by-Country Snapshot
- What Your Policy Needs to Address Before Study Start
- How a LatAm-Experienced CRO Helps You Get This Right
- FAQs
- Conclusion
Clinical trial insurance is one of those line items that sponsors tend to treat as an afterthought — something to sort out once the protocol is finalized and site contracts are signed. In Latin America, that approach creates real risk.
Regulatory bodies across the region require proof of adequate coverage before a study can begin. Ethics committees review insurance documentation as part of their submission packages. And the specific requirements vary by country, device class, and study phase in ways that routinely catch first-time LatAm sponsors off guard.
This article covers what clinical trial insurance actually covers in a LatAm context, what regulators and ethics committees typically require, how requirements differ across key jurisdictions, and what you should confirm with your CRO before your study start date.
What Clinical Trial Insurance Covers in a Trial Context
Clinical trial insurance — sometimes called clinical trial liability insurance or investigational product liability insurance — protects sponsors, investigators, and participants against financial harm arising from trial-related adverse events.
For a first-in-human or early feasibility study, core coverage areas typically include:
- Participant injury or death caused by the investigational device or drug
- Medical expenses for trial-related adverse events not covered by the participant's own health insurance
- Legal defense costs if a participant or their family brings a claim against the sponsor or investigator
- Indemnification for sites and investigators named in the study agreement
Some policies also cover trial interruption and data loss, though those riders are less universally required by regulators and more relevant to sponsors managing operational risk.
What the policy does not cover matters just as much. Pre-existing conditions, injuries unrelated to the investigational product, and events outside the protocol-defined treatment window are typically excluded. The exclusion language in your policy deserves as much attention as the headline coverage amount.
Why Latin America Has Its Own Insurance Considerations
Running a first-in-human study in Latin America offers real structural advantages. Ethics and regulatory approvals in jurisdictions like Panama, El Salvador, Chile, and the Dominican Republic are observed in 30 to 90 days — compared to 6 to 12 months in the US or EU. That speed is why sponsors working through a structured program like bioaccess®'s FIH-12 program can reach a submission-ready evidence package within 12 months.
But that same regulatory infrastructure carries specific insurance expectations. Most LatAm health authorities and institutional ethics committees — known variously as Comités de Ética en Investigación, Comités de Bioética, or Comités de Revisión Institucional depending on the country — require sponsors to submit insurance documentation as a condition of approval, not as a post-approval formality.
Several factors make LatAm insurance requirements distinct from what US sponsors are used to:
Local policy language requirements. Some countries require that the policy document be translated into Spanish and notarized locally. A certificate of insurance issued by a US carrier in English may not satisfy the submission requirement on its own.
Named insured requirements. Ethics committees in several jurisdictions require that the local principal investigator and clinical site be named as additional insureds on the sponsor's policy. This is not always standard in US-issued policies and may require an endorsement.
Minimum coverage thresholds. No single regional standard exists. Individual country requirements or ethics committee guidelines often specify minimum per-participant or per-occurrence limits, and those thresholds are set by the reviewing body, not by a pan-regional rule.
Policy territory clauses. A US-domiciled sponsor's general liability or product liability policy may exclude coverage for trials conducted outside the United States. You need to confirm that your policy's territory clause explicitly extends to every country where your study will run.
Country-by-Country Snapshot
Requirements are not uniform across the 19 Latin American and Caribbean markets where LatAm-focused FIH trials operate. Here is a practical overview of what sponsors encounter in the primary jurisdictions.
Panama
MINSA/CNBI reviews insurance documentation as part of the clinical trial authorization package. Ethics committees typically require a certificate of insurance demonstrating coverage for trial-related participant injury, with the site and investigator named as additional insureds. Panama's approval timelines are among the fastest in the region, but insurance documentation gaps are a common cause of resubmission requests that push that timeline back.
Chile
ISP (Instituto de Salud Pública) and MINSAL-affiliated ethics committees are thorough in their documentation review. Requirements here tend to be more formalized — some committees specify minimum coverage amounts per participant, and sponsors should expect requests for a Spanish-language policy summary. In some cases, a legal opinion from a Chilean attorney confirming that the coverage is valid under Chilean law may also be required.
El Salvador
El Salvador's SRS/CNEIS framework includes insurance review as part of ethics committee submissions. Requirements are generally consistent with Panama's, though the reviewing committee may have specific expectations about the policy's validity period aligning with the study's projected duration plus a defined post-study coverage window.
Dominican Republic
The Dominican Republic's ethics review process includes insurance verification. Sponsors should confirm that their policy covers the full enrollment and follow-up period — ethics committees here have flagged policies that expire before the study's anticipated last patient last visit date.
Brazil
Brazil (ANVISA and CONEP) has some of the most detailed clinical research regulations in the region. Insurance or equivalent financial guarantee documentation is required, and CONEP's review process is comprehensive. Brazil is not always the first jurisdiction for a first-in-human study given its longer approval timelines relative to Panama or Chile, but sponsors expanding a LatAm program into Brazil need to plan for more detailed insurance documentation requirements from the outset.
Colombia
INVIMA requires that sponsors demonstrate financial responsibility for participant injury. Colombia's ethics committees have become more rigorous in recent years, and sponsors should approach insurance documentation here with the same level of preparation they would bring to a US IRB submission.
What Your Policy Needs to Address Before Study Start
Before your first site activation in any LatAm jurisdiction, work through this checklist with your insurance broker and your CRO:
Territory confirmation. Does your policy explicitly cover clinical research activities in each country where your study will run? Get this in writing from your carrier — not a verbal assurance.
Named insureds. Are the local principal investigator, the clinical site, and any sub-investigators named or covered as additional insureds? Some ethics committees will not accept a policy that names only the sponsor.
Coverage period. Does the policy cover the full study period, including post-study follow-up? Many first-in-human protocols include follow-up windows of 30 to 90 days or longer after the last intervention. Your policy needs to remain valid through that window.
Per-participant limits. Review any country-specific or ethics committee-specific minimum limits and confirm your policy meets or exceeds them.
Language and notarization. Determine whether each jurisdiction requires a translated and/or notarized version of the policy or certificate, and build that into your submission timeline — not as an afterthought.
Claims reporting obligations. Understand how your policy handles adverse event reporting in the context of a claim. Some policies require notification within a specific window after an adverse event, which needs to align with your protocol's SAE reporting procedures.
Runoff coverage. If the sponsor is a startup and the policy lapses or the company undergoes a transaction during the study, what happens to coverage? Runoff or tail coverage provisions are worth discussing with your broker before the study starts — not after a corporate event forces the question.
How a LatAm-Experienced CRO Helps You Get This Right
Sponsors who have never run a study in Latin America often underestimate how much local knowledge matters in the insurance documentation process. The requirements are not published in a single, consolidated regulatory document. They live in ethics committee guidelines, health authority submission templates, and the institutional policies of individual sites — and they change.
A CRO with deep LatAm experience will know what each ethics committee and health authority currently expects, which documentation formats they accept, and where the common gaps appear in sponsor-submitted packages. That knowledge has a direct effect on your approval timeline.
bioaccess® structures its FIH-12 program around nine workstreams, one of which covers regulatory and ethics submission preparation. Insurance documentation is addressed as part of the submission package — not as a separate track that sponsors have to manage in parallel. The program's 12-month timeline guarantee from protocol to submission-ready evidence package depends on getting these details right early, and that starts with insurance.
If you are planning a first-in-human study in Latin America and want to understand how insurance requirements fit into the broader regulatory pathway for your device or compound, bioaccess® works with sponsors to map that process before a single document is submitted.
FAQs
Is clinical trial insurance required by law in Latin American countries?
Requirements vary by country. In most jurisdictions where first-in-human trials are common — Panama, Chile, El Salvador, the Dominican Republic, Colombia, and Brazil — ethics committees and health authorities require proof of insurance or equivalent financial coverage as a condition of study approval. The specific form and minimum amounts differ by jurisdiction and reviewing body.
Can a US-issued policy cover clinical trials in Latin America?
Yes, but only if the policy's territory clause explicitly extends to the countries where the study will run. Many standard US general liability or product liability policies exclude international clinical research activities. Get written confirmation from your carrier — don't rely on an assumption based on policy language.
Do local investigators need to be named on the sponsor's policy?
In many LatAm jurisdictions, yes. Ethics committees in Panama, Chile, and Colombia, among others, commonly require that the local principal investigator and clinical site be named as additional insureds. This typically requires an endorsement to the base policy.
How far in advance should sponsors secure clinical trial insurance for a LatAm study?
The insurance process should begin at the same time as protocol development — not after the protocol is finalized. Ethics committee submission packages in most LatAm countries require insurance documentation upfront. Delays in securing or translating the policy are a common cause of resubmission requests that push back approval timelines.
What is the difference between clinical trial insurance and product liability insurance for medical devices?
Product liability insurance covers claims arising from a commercially marketed product. Clinical trial insurance covers claims arising specifically from a participant's involvement in a study, including adverse events related to the investigational device or drug during the trial period. Sponsors running first-in-human studies need clinical trial-specific coverage — not just commercial product liability.
What happens if a participant is injured and the sponsor's policy does not cover the jurisdiction?
The sponsor remains legally and ethically responsible for the participant's care and compensation regardless of whether the insurance policy responds. In practice, that means the sponsor bears the cost directly and may face regulatory consequences — including study suspension — if the coverage gap is discovered by the health authority or ethics committee.
Does the insurance requirement differ for medical devices versus drugs or biologics in Latin America?
The general requirement for participant injury coverage applies across device, drug, and biologic studies. However, the specific documentation formats, minimum limits, and review processes can differ. Some LatAm health authorities maintain separate regulatory pathways for devices versus drugs, and the associated insurance documentation expectations may reflect those differences. Working with a CRO that has experience across both categories helps sponsors navigate these distinctions accurately.
Conclusion
Clinical trial insurance in Latin America is not a checkbox. It is a submission requirement, an ethics committee expectation, and a practical protection for your participants, your sites, and your program. Getting the documentation right before study start — with the correct territory coverage, named insureds, policy period, and language requirements for each jurisdiction — is one of the less visible but genuinely consequential parts of running a successful LatAm FIH study.
If you are mapping out a first-in-human program and want to understand how insurance fits into the full regulatory and operational picture, start with a clear view of your country route and submission requirements. bioaccess® can help you build that map before you commit to a timeline.
WordPress Category: Navigating Regulatory Landscapes in Latin America
Leave a Reply